Meeting News Coverage

Eleven Biotherapeutics releases data on protein therapies for dry eye, DME

Eleven Biotherapeutics released new data on two novel protein therapeutics at the Association for Research in Vision and Ophthalmology meeting.

The data show the key role of cytokine biology to target ocular surface and retinal disease, according to an Eleven Biotherapeutics news release.

Presentations highlighted EBI-005, an interleukin-1 signaling inhibitor designed for topical treatment of dry eye disease, and EBI-029, an interleukin-6 inhibitor optimized for localized ocular administration in diabetic macular edema.

EBI-005 is currently undergoing a phase 3 pivotal study in patients with dry eye disease and a phase 2 clinical study in patients with allergic conjunctivitis. EBI-029 is in preclinical development.

A poster presentation on a phase 1a/2b clinical study of EBI-005 showed that in 74 patients with moderate to severe dry eye disease, the agent significantly improved Ocular Surface Disease Index pain scores at 6 weeks, the release said.

Treatment with EBI-005 was safe and well-tolerated, the release said.

Another poster on a phase 1/2b study showed that mean artificial tear use over 6 weeks was 11.1 vials for patients treated with EBI-005 and 31 vials for those who received a placebo; the difference was statistically significant (P = .005), the release said.

Eleven Biotherapeutics released new data on two novel protein therapeutics at the Association for Research in Vision and Ophthalmology meeting.

The data show the key role of cytokine biology to target ocular surface and retinal disease, according to an Eleven Biotherapeutics news release.

Presentations highlighted EBI-005, an interleukin-1 signaling inhibitor designed for topical treatment of dry eye disease, and EBI-029, an interleukin-6 inhibitor optimized for localized ocular administration in diabetic macular edema.

EBI-005 is currently undergoing a phase 3 pivotal study in patients with dry eye disease and a phase 2 clinical study in patients with allergic conjunctivitis. EBI-029 is in preclinical development.

A poster presentation on a phase 1a/2b clinical study of EBI-005 showed that in 74 patients with moderate to severe dry eye disease, the agent significantly improved Ocular Surface Disease Index pain scores at 6 weeks, the release said.

Treatment with EBI-005 was safe and well-tolerated, the release said.

Another poster on a phase 1/2b study showed that mean artificial tear use over 6 weeks was 11.1 vials for patients treated with EBI-005 and 31 vials for those who received a placebo; the difference was statistically significant (P = .005), the release said.

    See more from Association for Research in Vision and Ophthalmology